Introduction {#sec1-1}
============

The burden of breast cancer, as the most prevalent malignant neoplasm among females globally \[[@ref1]\] and in Iraq specifically \[[@ref2]\], has been illustrated comprehensively in numerous surveys that emphasised the importance of its early detection and control \[[@ref3]\], \[[@ref4]\], \[[@ref5]\], \[[@ref6]\], \[[@ref7]\], \[[@ref8]\]. Evidence suggests that patients diagnosed with the disease exhibit different clinical behaviour according to the various pathological and biological characteristics of the tumour; thus, recommending different therapeutic strategies.

Earlier analytic studies on gene expressions revealed that the response of the mammary carcinoma cell to treatment is determined by intrinsic molecular characteristics that could be probed. The pioneer molecular portrait presented by Sorlie et al., classified breast cancer into five intrinsic subtypes with distinct clinical outcomes, i.e., luminal A, luminal B, HER2 over-expression, basal and normal-like tumours \[[@ref9]\], \[[@ref10]\]. Later on, immunohistochemical (IHC) assays categorised breast cancer into three major adopted phenotypes; the Luminal, HER2 enriched and Triple Negative (TN).

TN breast cancer is considered a heterogeneous group that comprises the basal subtypes which are reported to be more frequent among younger age patients and exhibit more aggressive nature with limited therapeutic options and high risk of recurrence \[[@ref11]\], \[[@ref12]\], \[[@ref13]\]. On the other hand, the luminal-like tumours, that express hormone receptor, are the most common subtypes that carry a good prognosis. They usually respond well to hormonal treatment but poorly to conventional chemotherapy. While Luminal A could be adequately controlled with endocrine treatment, luminal B (triple positive TP) phenotypes often tend to be more proliferative, yielding relatively higher grade and recurrent tumours; thus, recommending combined chemotherapy and hormonal treatment \[[@ref10]\], \[[@ref14]\].

Whereas few previous studies registered the various breast cancer IHC subtypes among Iraqi patients \[[@ref5]\], \[[@ref6]\], \[[@ref15]\], \[[@ref16]\], \[[@ref17]\], \[[@ref18]\], reported data on their different behaviours and outcomes to remain scanty.

This study aims at providing further information on the clinical and pathological presentations of TN Iraqi breast cancer patients as compared to the other variants focusing on the triple positive (TP) and HER2 enriched phenotypes.

Material and Methods {#sec1-2}
====================

The present study comprised 486 Iraqi female patients with a histopathologically confirmed diagnosis of mammary carcinoma registered between 2015 and 2017 at the Oncology Teaching Hospital and the National Cancer Research Center, Baghdad, Iraq. The studied clinical and pathological parameters were obtained from the case sheet records and pathology reports of the corresponding patients and included the age at diagnosis, tumour type, grade and size, lymph node status and the stage of the disease at presentation. Written consents were obtained from all the patients enrolled in the present work to use the relevant recorded information and approval of the study design was given by the Ethical Committee of the National Cancer Research Center of Baghdad University following the ethical standards laid down by the Declaration of Helsinki.

The reported data were reassessed to document the requested variables. Pathologically, breast cancers were typed according to the WHO classification \[[@ref19]\] and graded following the modified Nottingham Bloom-Richardson categorisation \[[@ref20]\]. The UICC TNM System was adopted to classify the clinical stage of the disease at presentation \[[@ref21]\]. Evaluation of the Estrogen receptor (ER), Progesterone receptor (PR) and HER2 contents of the primary tumours was performed through IHC staining of the formalin-fixed paraffin-embedded tissue blocks using Dako kits (Denmark) including the specific monoclonal antibodies \[[@ref14]\], \[[@ref15]\].

The major registered receptor-defined subtypes were: - Luminal A (ER/PR positive/HER2 negative); - Luminal B/Triple Positive (ER/PR positive/HER2 positive); - HER2 Enriched (ER/PR negative/HER2 positive); and - Triple Negative (ER/PR negative/HER2 negative).

Other recorded subtypes included: - ER (positive)/PR (negative)/HER2 (positive); - ER (negative)/PR (positive)/HER2 (positive); - ER (positive)/PR (negative)/HER2 (negative); and - ER (negative)/PR (positive)/HER2 (negative).

Accordingly, patients were classified into five groups: TN (Group I); TP (Group II); Luminal A (Group III); HER2 enriched (Group IV); and all other subtypes (Group V).

Statistical correlation to compare the demonstrated clinical and pathological features of the different breast cancer subtypes was carried out using SPSS version 16.0 statistical program. Categorical data were presented by frequencies and percentages. Chi-square test was used to assess the association between the different variables. *P* values, less or equivalent to 0.05, were considered significant.

Results {#sec1-3}
=======

IHC examination of the diagnosed breast cancer tissue specimens belonging to 486 patients revealed that the total rates of ER, PR and HER2 positive tumour contents were equivalent to 68.5%, 66.2% and 29.6% respectively. The major registered subtype was the Luminal A (E+/P+/H-) which was encountered in 230 patients (47.3%), followed by Triple Negative (E-/P-/H-) in 71 patients (14.6%), Luminal B/Triple Positive (E+/P+/H+) in 66 patients (13.6%) and HER2 Enriched (E-/P-/H+) in 56 patients (11.5%). Other encountered phenotypes were rare and included in order of frequency: (E+/P-/H-) in 22 cases (4.5%); (E-/P+/H-) in 19 cases (3.9%); (E+/P-/H+) in 15 cases (3.1%) and (E-/P+/H+) in seven cases (1.4%) ([Figure 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}).

![Frequency distribution of Iraqi breast cancer IHC subtypes](OAMJMS-7-3534-g001){#F1}

###### 

Overall rates of the reported breast cancer subtypes among Iraqi patients

          IHC Subtype                 ER[\*](#t1f1){ref-type="table-fn"} Status   PR[\*\*](#t1f2){ref-type="table-fn"} Status   HER2[\*\*\*](#t1f3){ref-type="table-fn"} Status   IHC Phenotypes   Total No.   Total %
  ------- --------------------------- ------------------------------------------- --------------------------------------------- ------------------------------------------------- ---------------- ----------- ---------
  1       Luminal B/Triple Positive   E+                                          P+                                            H+                                                E+/P+/H+         66          13.6
  2       Triple Negative             E-                                          P-                                            H-                                                E-/P-/H-         71          14.6
  3       Luminal A                   E+                                          P+                                            H-                                                E+/P+/H-         230         47.3
  4       HER-2 Enriched              E-                                          P-                                            H+                                                E-/P-/H+         56          11.5
  5       E+/P-/H+                    E+                                          P-                                            H+                                                E+/P-/H+         15          3.1
  6       E-/P+/H+                    E-                                          P+                                            H+                                                E-/P+/H+         7           1.4
  7       E+/P-/H-                    E+                                          P-                                            H-                                                E+/P-/H-         22          4.5
  8       E-/P+/H-                    E-                                          P+                                            H-                                                E-/P+/H-         19          3.9
  Total                                                                                                                                                                                            486         100

Total Estrogen Receptor rate: 68.5%;

Total Progesterone Receptor rate: 66.2%;

Total HER2 rate: 29.6%.

[Table 2](#T2){ref-type="table"} illustrates the clinical and pathological presentations of the TN breast cancer subtype compared to the TP/Luminal B, HER2 enriched and Luminal A phenotypes. Significant differences were noted among the different studied groups concerning the age of the patients at presentation (p \< 0.05). Patients exhibiting the TN subtype were significantly younger than the rest of the groups (69% under the age of 50 years versus 52% overall).

###### 

Clinical and tumour characteristics categorized according to the examined breast cancer subtypes

                     Group I E-/P-/H-TN[\*](#t2f1){ref-type="table-fn"}   Group II E+/P+/H+TP[\*\*](#t2f2){ref-type="table-fn"} Luminal B   Group III E+/P+/H- Luminal A   Group VI E-/P-/H+Her2- Enriched   Group V All other Subtypes   Overall Total Subtypes   p-value                                          
  ------------------ ---------------------------------------------------- ----------------------------------------------------------------- ------------------------------ --------------------------------- ---------------------------- ------------------------ --------- -------- ---- -------- ----- --------- -------------
  Age (years)                                                                                                                                                                                                                                                                                                       11.863.
  \< 50              49                                                   69.0                                                              33                             50                                107                          46.5                     28        50       36   57.1     253   (52.1)    P=0.0184
  =\>50              22                                                   31.0                                                              33                             50                                123                          53.5                     28        50       27   42.9     233   (47.9)    Significant
                                                                                                                                                                                                                                                                                                                    
  Tumour Type                                                                                                                                                                                                                                                                                                       
  Ductal             56                                                   78.9                                                              53                             80.3                              171                          74.4                     48        85.7     49   77.8     377   (77.6)    
  Lobular            5                                                    7                                                                 4                              6.1                               21                           9.1                      1         1.8      3    4.8      33    (6.8)     7.259
  In situ            0                                                    0                                                                 2                              3.0                               11                           4.7                      1         1.8      1    1.6      11    (2.3)     p=0.848
  Others/mixed       4                                                    5.6                                                               2                              3.0                               13                           5.7                      2         3.6      4    6.3      18    (3.7)     NS
  Unknown            6                                                    8.4                                                               5                              7.6                               14                           6.1                      4         7.1      6    9.5      47    (9.7)     
                                                                                                                                                                                                                                                                                                                    
  Tumour Grade                                                                                                                                                                                                                                                                                                      
  I                  2                                                    2.8                                                               0                              0                                 14                           6                        0         0        0    0        16    (3.3)     
  II                 50                                                   70.4                                                              41                             62.1                              153                          66.5                     35        62.5     39   61.9     318   (65.4)    13.0145
  III                13                                                   18.3                                                              12                             18.1                              32                           13.9                     15        26.8     14   22.2     86    (17.7)    p=0.016
  Unknown            6                                                    8.4                                                               13                             19.7                              31                           13.5                     6         10.7     10   15.9     66    (13.6)    NS
                                                                                                                                                                                                                                                                                                                    
  Tumour Size                                                                                                                                                                                                                                                                                                       
  T1                 11                                                   15.5                                                              10                             15.1                              48                           20.9.                    6         10.7     13   20.6     88    (18.1)    
  T2                 34                                                   47.9                                                              43                             65.2                              128                          7                        35        62.5     39   61.9     279   (57.4)    16.321
  T3                 18                                                   25.3                                                              9                              13.6                              31                           13.5                     8         14.2     5    7.9      71    (14.6)    P=0.4308
  T4                 4                                                    5.6                                                               2                              3                                 10                           4.3                      2         3.6      2    3.2      20    (4.1)     NS
  Tx                 4                                                    5.6                                                               2                              3                                 13                           5.6                      5         8.9      4    6.3      28    (5.8)     
                                                                                                                                                                                                                                                                                                                    
  LN Status                                                                                                                                                                                                                                                                                                         
  N0                 20                                                   28.1                                                              20                             30.3                              79                           34.3                     14        25       20   31.7     153   (31.5)    2.045
  N+                 42                                                   59.1                                                              40                             60.6                              135                          58.7                     38        67.9     39   61.9     294   (60.5)    p=0.563
  Nx                 9                                                    12.7                                                              6                              9                                 16                           7                        4         7.1      4    6.3      39    (8.0)     NS
                                                                                                                                                                                                                                                                                                                    
  Stage              37                                                   57.8                                                              37                             60.7                              133                          61.9                     20        38.5     35   59.3     262   (53.90)   9.6886.
  I & II             27                                                   42.2                                                              24                             39.3                              82                           38.1                     32        61.5     24   40.7     189   (38.9)    P=0.0460
  III & IV Unknown   7                                                                                                                      5                                                                15                                                    4                  4             35    (7.2)     Significant
                                                                                                                                                                                                                                                                                                                    
  Total              71                                                   (14.6)                                                            66                             (13.6)                            230                          (47.3)                   56        (11.5)   63   (13.0)   486   \(100\)   

Triple Negative;

Triple Positive

Although the rate of Lobular carcinoma was higher among group III (Luminal A), yet the differences in frequencies of the various histologic types of breast cancer were not statistically significant.

Likewise, whereas the highest frequency of poorly differentiated mammary carcinomas was observed among group IV (HER2) subtype (26.8% versus 17.7% overall), such difference was not significant. Larger size tumours (T3 and T4) were more common in patients with the group I (TN) phenotype (30.9% versus 16.6%, 17.8%, 17.8% and 11.1% in groups II, III, and IV and V respectively). More than two-thirds of patients in group IV (HER2) presented with metastatic lymph node involvement (67.9%); that rate was higher than the other subtypes. Nevertheless, Chi-square statistics failed to reveal any significant variations between the studied groups regarding tumour size or nodal status. On the other hand, a statistical difference in the distribution of breast cancer stages was displayed (p \< 0.05); with significantly more advanced stages (III and IV) noted in patients with HER2 enriched subtypes (61.5%) compared to 42.2%, 39.3% and 38.1% in groups I, II and III respectively.

Discussion {#sec1-4}
==========

Cancer is currently forming a major public health concern in Iraq; being responsible for the second cause of death among the general population \[[@ref2]\], \[[@ref22]\], \[[@ref23]\]. Iraqi studies, in particular, have displayed the emerging dilemma of controlling breast cancer, the most common registered malignancy, which is increasingly diagnosed alarmingly among middle-aged females at quite advanced stages \[[@ref4]\], \[[@ref5]\], \[[@ref6]\], \[[@ref7]\], \[[@ref8]\], \[[@ref23]\]. It has been well established that racial disparities contribute to the various morphologies and presentations of breast cancer among patients in different ethnic groups reflecting the reported discrepancy in incidence, prognosis and survival from the disease \[[@ref24]\], \[[@ref25]\], \[[@ref26]\], \[[@ref27]\]. The molecular diversity of breast cancer illustrated in genomic analytic studies promoted the development of targeted therapies to the genetic alterations that drive certain identified cancer subtypes. The registered frequencies of ER+, PR+ and HER2+ breast cancers in the present work were 68.5%, 66.2% and 29.6% respectively. Whereas the corresponding figures from western studies are significantly higher for ER+ and PR+ breast cancers, they are statistically lower for HER2+ tumours contributing to better outcomes of the disease in well-developed regions of the world \[[@ref5]\], \[[@ref24]\], \[[@ref25]\], \[[@ref26]\], \[[@ref27]\], \[[@ref28]\], \[[@ref29]\].

As observed in earlier studies from Iraq \[[@ref5]\], \[[@ref15]\], \[[@ref16]\], \[[@ref17]\], \[[@ref18]\] and the literature \[[@ref9]\], \[[@ref10]\], \[[@ref11]\], \[[@ref12]\], \[[@ref13]\], \[[@ref14]\], \[[@ref24]\], \[[@ref25]\], \[[@ref26]\], \[[@ref27]\], \[[@ref28]\], \[[@ref29]\], \[[@ref30]\], \[[@ref31]\], \[[@ref32]\], \[[@ref33]\] the major registered breast cancer subtype was Luminal A (47.3%) that comprises positive hormone receptors in the absence of HER2 overexpression; stimulating the favorable biological behavior of the disease in the affected patients. While the displayed rate is close \[[@ref29]\] and almost higher than those documented in surveys from Arab countries \[[@ref30]\], \[[@ref31]\], yet it is significantly lower than those reported in Western studies \[[@ref5]\], \[[@ref24]\], \[[@ref25]\], \[[@ref26]\], \[[@ref27]\], \[[@ref28]\]. Focusing on molecular characteristics and management implications of breast cancer in Arab populations, it was noted that disparities in these regions were not only confined to the clinicopathological features but existed as well at the molecular levels as reflected in the relevant genomic expression profiles \[[@ref5]\], \[[@ref27]\], \[[@ref29]\], \[[@ref30]\], \[[@ref31]\]. A recent study on the comparative behaviour of breast cancer among Iraqi and British patients pointed out to heterogeneity of the underlying tumour biology that reflected genetic susceptibility. The authors concluded that the significantly younger ages and advanced stages at the presentation of breast cancer among Iraqi patients, associated with the higher rates of TN and HER2 enriched phenotypes, recommended comprehensive assessment of the surrogate subtypes to ensure effective approaches in the management of the disease in Iraq \[[@ref5]\]. Such higher rates of aggressive breast cancer subtypes among patients from low-middle income countries compared to those living in high-income societies were illustrated in earlier surveys \[[@ref27]\], \[[@ref29]\], \[[@ref30]\], \[[@ref31]\], \[[@ref32]\], \[[@ref33]\]. The second prevalent breast cancer subtype observed in the present work (14.6%) was the TN which is characterised by the negative expressions of ER, PR and HER2.

Interestingly that frequency was close to the rate recorded in the Annual Report to the Nations on the incidence of breast cancer subtypes in the US \[[@ref28]\]; highlighting the significantly low prevalence of hormone receptor-negative tumours among the American patients. Consistent with the findings displayed earlier by other investigators, patients bearing this subtype in our study were significantly younger than those exhibiting the other phenotypes and presented with larger size tumours at the time of diagnosis \[[@ref11]\], \[[@ref12]\], \[[@ref13]\]. However, they were less likely to have poorly differentiated tumours and positive lymph node involvement than group IV; the HER2-enriched tumour counterparts. Whereas previous reports showed that TN breast cancer tumours with more positive axillary lymph node, higher clinical stages and histological grades leading to aggressive clinical behaviour \[[@ref34]\], \[[@ref35]\], others demonstrated that TN encompasses a wide spectrum of entities possessing different biological and clinical attitudes including low-grade disease with indolent behaviour and favourable outcome \[[@ref36]\], \[[@ref37]\].

In general, patients exhibiting the HER2 enriched variant, which constituted 11.5% of total subtypes in the present work, displayed the highest frequency of poorly differentiated cancers and metastatic lymph nodes. It has been recorded in the literature that between 15-25% of breast cancers possess overexpression of HER2 and yield unfavourable clinical outcome \[[@ref28]\], \[[@ref38]\], \[[@ref39]\]. The registered rates of HER2 + subtypes in the Arab series are quite higher \[[@ref29]\], \[[@ref40]\]; pointing out to the elevated prevalence of less differentiated tumours in the region \[[@ref29]\], \[[@ref30]\], \[[@ref31]\], \[[@ref40]\], \[[@ref41]\]. Such regional and ethnic differences in the grades of the tumour are most probably related to genetic, biological and environmental factors. TP Luminal B subtype formed about 13.6% in the present study; close to the findings reported in previous studies from Iraq \[[@ref5]\], \[[@ref6]\], \[[@ref15]\], \[[@ref16]\], \[[@ref18]\], and the neighboring countries \[[@ref41]\], \[[@ref42]\]. In a recent survey performed on a cohort of Iraqi patients presenting with breast cancer, no significant differences were noted in the clinicopathological presentations of patients with this phenotype compared to the others apart from the variation in the distribution of tumour types; where infiltrative ductal carcinomas were more common \[[@ref16]\]. That was in contrast to the findings observed in another study which showed that invasive ductal carcinomas were preponderant among the TN subtypes \[[@ref36]\]. Similar to other studies \[[@ref43]\], the data of this work did not reveal any statistical differences in the distribution of the histological types among the examined groups, though the rate of lobular carcinoma was more common among patients with Luminal A.

Concerning the breast cancer stage at presentation, our results revealed a significant difference in the distribution among the various groups (p \< 0.05); with the highest frequency of advanced stages (III and IV) being observed among those harbouring the HER2 enriched subtypes. It has been displayed in the literature that hormone-receptor-positive breast cancer expressions are often associated with earlier stages at presentation and that HER2+ impact is reflected by poorly differentiated tumours and advanced stages \[[@ref39]\].

A recently published Iraqi study correlating the stage of breast cancer at the time of diagnosis with the clinicopathological characteristics of the affected patients demonstrated that 64.4% and 67.2% exhibiting Luminal A and Luminal B subtypes respectively were diagnosed at Stages I and II whereas 68% and 62% of those harbouring the TN and HER2+ respectively presented at advanced stages (III and IV) \[[@ref6]\]. Comparative retrospective evaluation of the clinical features and survival outcomes of 1134 invasive breast cancer subtypes showed that the overall five-year survival was almost similar in TN and HER2 subtypes, nevertheless, subjects with HER2 presented at later stages with more frequent local recurrences \[44\].

In conclusion, patients within the TN group were statistically younger and exhibited larger tumour sizes than others. On the other hand, poorly differentiated tumours and metastatic lymph node involvement were more commonly encountered among patients with HER2 subtype who presented with significantly more advanced stages at the time of diagnosis. Adopting molecular subtype classification of breast cancer, as a cost-effective, reliable clinical investigation in countries with limited resources, is recommended to provide a feasible tool for assessing the response to therapy and to serve as a valuable prognostic marker in the management of aggressive forms of the disease among younger patients.
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